Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease

Abstract : Hereditary amyloidogenic transthyretin (ATTRv) amyloidosis with polyneuropathy (also known as familial amyloid polyneuropathy) is a condition with adult onset caused by mutation of transthyretin (TTR) and characterized by extracellular deposition of amyloid and destruction of the somatic and autonomic PNS, leading to loss of autonomy and death. This disease represents a model of the scientific and medical progress of the past 30 years. ATTRv amyloidosis is a worldwide disease with broad genetic and phenotypic heterogeneity that presents a diagnostic challenge for neurologists. The pathophysiology of the neuropathy is increasingly understood and includes instability and proteolysis of mutant TTR leading to deposition of amyloid with variable lengths of fibrils, microangiopathy and involvement of Schwann cells. Wild-type TTR is amyloidogenic in older individuals. The main symptoms are neuropathic, but the disease is systemic; neurologists should be aware of cardiac, eye and kidney involvement that justify a multidisciplinary approach to management. Infiltrative cardiomyopathy is usually latent but present in half of patients. Disease-modifying modifying therapeutics that have been developed include liver transplantation and TTR stabilizers, both of which can slow progression of the disease and increase survival in the early stages. Most recently, gene-silencing drugs have been used to control disease in the more advanced stages and produce some degree of improvement.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : mardi 22 février 2022 - 11:13:15
Dernière modification le : lundi 29 août 2022 - 10:10:49




David Adams, Haruki Koike, Michel Slama, Teresa Coelho. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nature Reviews Neurology, Nature Publishing Group, 2019, 15 (7), pp.387-404. ⟨10.1038/s41582-019-0210-4⟩. ⟨hal-03584073⟩



Consultations de la notice